Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
I-MAB ( (IMAB) ) has shared an announcement.
On May 28, 2025, I-MAB announced the appointment of Dr. Sean Cao as an independent member of its board of directors, effective immediately. Dr. Cao, who brings extensive experience in the pharmaceutical and biotech industries, will also serve on the Audit and Compensation Committees. This strategic appointment is expected to strengthen I-MAB’s leadership and enhance its governance as the company continues to advance its pipeline of innovative therapies.
The most recent analyst rating on (IMAB) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on I-MAB stock, see the IMAB Stock Forecast page.
Spark’s Take on IMAB Stock
According to Spark, TipRanks’ AI Analyst, IMAB is a Neutral.
The overall stock score of 45 reflects I-MAB’s substantial financial challenges, particularly in terms of profitability and cash flow generation, which heavily impact its financial performance. Despite a modest technical uptrend, valuation metrics point to significant risks, with ongoing losses and a negative P/E ratio limiting its appeal. The absence of recent earnings call data or notable corporate events further solidifies the overall cautious outlook.
To see Spark’s full report on IMAB stock, click here.
More about I-MAB
I-MAB is a biopharmaceutical company focused on the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly in the areas of immuno-oncology and autoimmune diseases.
Average Trading Volume: 227,293
Technical Sentiment Signal: Sell
Current Market Cap: $92.36M
For an in-depth examination of IMAB stock, go to TipRanks’ Stock Analysis page.